Lv11
100 积分 2024-09-01 加入
OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)
19天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
19天前
已完结
Soluble TL1A is sufficient for activation of death receptor 3
19天前
已完结
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
1个月前
已完结
Agonistic anti-PD-1 antibodies downregulate autoantibody development in lupus model mice
1个月前
已完结
Testing of monoclonal antibodies against the T-cell receptor associated with ankylosing spondylitis
1个月前
已关闭
Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials
3个月前
已完结
How to build anti-PD1 agonist antibodies
3个月前
已完结
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
3个月前
已完结
Autoimmune TCRs cross-react with microbial and self-antigens
3个月前
已完结
皖公网安备34019202002308
